ASCO 2017: Next-generation sequencing of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer
Chicago, IL (UroToday.com) As patient selection becomes a more critical part of prostate cancer management, particularly in advanced prostate cancer, there has been growing emphasis on using genomic data to help stratify patients. However, greater understanding regarding the genomic landscape of advanced prostate cancer is required, particularly in large datasets. In this study, the MSKCC and Cornell groups utilize a large combined dataset of 1038 prospectively collected tumors from 896 patients to help provide greater understanding of the genomic characterization of advanced prostate cancer.
ASCO 2017: A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209
Chicago, IL (UroToday.com) Pelareorep (REO) is a pharmaceutical human reovirus, and as an oncolytic virus, it appears to preferentially lyse cancer cells. With prior efficacy demonstrated in phase 1 and 2 trials in head & neck, melanoma, pancreatic, lung, ovarian, and colorectal cancers, the authors of this study have now introduced it into the management for prostate adenocarcinoma.
ASCO 2017: The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials
Chicago, IL (UroToday.com) Metastatic prostate cancer (mPCa) used to be defined by the receipt of chemotherapy (docetaxol) or not. However, with the introduction novel AR axis therapies such as enzalutamide and abiraterone, among others, the entire paradigm of mPCa has changed.
ASCO 2017: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients
Chicago, IL (UroToday.com) In the last year, the S-TRAC randomized controlled trial (RCT)  demonstrated that patients receiving adjuvant sunitinib vs placebo for high risk renal cell carcinoma (RCC) have improved disease-free survival (DFS). Similarly, at the same session this morning, it was reported that patients treated with adjuvant pazopanib (800 mg) may also have improved DFS .
ASCO 2017: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)
Chicago, IL (UroToday.com) On the heels of two randomized controlled trials (RCTs) recently published assessing adjuvant TKIs in the setting of patients treated with radical nephrectomy for locally advanced renal cell carcinoma (RCC) [1,2], Dr. Motzer and colleagues presented their findings at the 2017 ASCO annual meeting of another phase III RCT assessing adjuvant pazopanib vs placebo in these high risk patients.
ASCO 2017: Can Subgroup Analyses Identify Enrichment Strategies for Adjuvant RCC Studies?
Chicago, IL (UroToday.com) Dr. Daniel Heng from Calgary, Canada provided the discussant talk following presentation of Abstract 4507 (Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT) ) and Abstract 4508 (Phase III trial of adjuvant sunitinib in patients with high-risk RCC: Validation of the 16-gene Recurrence Score in stage III patients ) at ASCO 2017 genitourinary cancer oral abstract session.
ASCO 2017: The clinical role of purified protein derivative skin test reaction in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guerin
Chicago, IL (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) still represents 70% of the patients who present with bladder cancer (BC). High-grade NMIBC represents a particularly troublesome cohort for whom clinical progression to MIBC remains a high risk, but for whom there are not many treatment options.